World's First AI-Designed Universal Vaccine Passes Human Trial at Cambridge

Scientists at the University of Cambridge have achieved a major breakthrough: the world's first vaccine designed entirely by artificial intelligence has passed its first human clinical trial. The experimental vaccine — called pEVAC-PS — was developed by Cambridge's Lab of Viral Zoonotics alongside university spin-out DIOSynVax, and results published June 5, 2026 in the Journal of Infection confirmed it is safe and produced no significant side effects in 39 healthy volunteers.

This isn't just another COVID vaccine. It's a completely new approach to how vaccines are designed — one that could protect against pandemics that haven't happened yet.

What Makes This Vaccine Different?

Traditional vaccines are reactive — scientists wait for a virus to emerge, study it, then build protection against it. That process takes years, and viruses don't wait.

The pEVAC-PS vaccine flips the model. Cambridge's AI analyzed the complete genetic sequence data of every known Sarbecovirus — the coronavirus family that includes COVID-19, SARS, and dozens of bat viruses with future pandemic potential. The AI then designed a single "super-antigen" containing features shared across the entire viral family.

The result: a vaccine that trains your immune system to recognize and fight an entire virus family — including variants that mutate and strains that haven't yet jumped from animals to humans.

"We've converted vaccine development from being reactive to being future proof," said Professor Jonathan Heeney, the research lead. "Our vaccines will continue to provide protection against viruses even as they mutate into new strains."

Remarkably, the vaccine triggered immune responses against bat coronaviruses that participants had never been exposed to — proving protection beyond anything previously vaccinated against.

The Trial and What's Next

The Phase 1 trial enrolled 39 volunteers aged 18–50 across NIHR research facilities in Southampton and Cambridge. Participants received escalating doses — 0.2mg to 1.2mg — at day zero and day 28. The vaccine is also needle-free, delivered via a painless micro fluid jet rather than a conventional injection.

Professor Andy Pollard of the Oxford Vaccine Group, who was not involved in the study, told BBC News: "It's fascinating data. Artificial intelligence is going to be a game changer for vaccine research — it will save lives."

A larger Phase 2 trial is now being planned to test effectiveness across a wider, more diverse population. The same AI platform is already being developed for influenza, HIV, and Ebola vaccines — meaning this breakthrough could extend far beyond coronaviruses.

Note: This is an early-stage Phase 1 trial confirming safety. Full effectiveness data requires further trials.

Key Takeaways

• University of Cambridge and DIOSynVax announced the world's first AI-designed vaccine passed Phase 1 human trials on June 5, 2026
• The pEVAC-PS vaccine targets the entire Sarbecovirus family — not just one strain
• 39 healthy volunteers confirmed it is safe with no serious side effects
• The vaccine is needle-free — delivered via micro fluid jet
• Triggered immune responses against bat coronaviruses participants had never encountered
• Phase 2 trial now planned; platform also being applied to flu, HIV, and Ebola
• Published in the peer-reviewed Journal of Infection